New AI tool accurately portrays metabolic states
RENAISSANCE can quantify unknown intracellular metabolic states, including metabolic fluxes.
List view / Grid view
RENAISSANCE can quantify unknown intracellular metabolic states, including metabolic fluxes.
In this four-part series, Dr Singh will discuss the challenges surrounding limited data quality, and some pragmatic solutions. In this first article, the key attributes that define data quality and its requirement for data scientists are elucidated.
There have been a slew of announcements over the past few months from AI-led biotechs around the potential of Large Language Models (LLM) in early drug discovery. In the third of a three-part series, Dr Raminderpal Singh presents some pragmatic guidelines for scientists in accessing and obtaining value from LLMs.
Recently there has been a flurry of announcements from AI-led biotechs around the potential of Large Language Models (LLM) in early drug discovery. In the second of a three-part series, Dr Raminderpal Singh presents an example of usage of ChatGPT, which demonstrates how accessible LLMs have become for lab scientists.
A new neural network computational model has been developed, which more closely reflects the abilities of real neurons and could advance AI progress.
The tool identified patients with high-risk disease, which normally goes unrecognised by traditional diagnostics.
Recently there have been a flurry of announcements from AI-led biotechs around the potential of Large Language Models (LLM) in early drug discovery. In the first of a three-part series, Dr Raminderpal Singh explores what LLMs are, how early stage biotechs can take advantage of them, and what challenges they…
Traditional wet lab scientists working on target discovery, drug identification and drug optimisation have an opportunity to catch up with their AI-enabled peers – but why should they, and how? In this article – the third of a three-part series – Dr Raminderpal Singh touches on the decisions that need…
The algorithm can accurately diagnose cases of lung adenocarcinoma, determining structural features that are statistically most significant for assessing disease severity and likelihood of tumour recurrence.
Traditional wet lab scientists working on target discovery, drug identification and drug optimisation have an opportunity to catch up with their AI-enabled peers – but why should they, and how? In this article – the second of a three-part series – Dr Raminderpal Singh touches on methods that are being…
Traditional wet lab scientists working on target discovery, drug identification and drug optimisation have an opportunity to catch-up with their AI-enabled peers – but why should they, and how? In this article – the first of a three-part series – Dr Raminderpal Singh seeks to demystify the topic by outlining…
Dr Richard Cote and Dr Ramaswamy Govindan of the Washington University School of Medicine elucidate how AI, particularly deep learning networks, could identify histopathologic features in non-small cell lung cancer, and impact the treatment approach for early-stage patients.
Researchers have developed an algorithm which could improve diagnostics of ovarian high-grade serous carcinoma.
We had the privilege of speaking to Dr Víctor Sebastián Pérez, Associate Director of Computational Drug Design, following his presentation at ELRIG UK 2023. He shares his insights into how Exscientia is using AI to design drug candidates for cancer treatment.
Researchers have developed a computational analysis tool which will improve patient stratification and enable personalised medicine.